Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
View in:
PubMed
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Qual Life Res. 2023 Jan; 32(1):183-196.
View in:
PubMed
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
View in:
PubMed
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022 01; 10(1).
View in:
PubMed
Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. J Natl Cancer Inst. 2021 11 02; 113(11):1484-1494.
View in:
PubMed
Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts. PLoS Comput Biol. 2021 06; 17(6):e1009020.
View in:
PubMed
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
View in:
PubMed
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011.
View in:
PubMed
Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States. J Natl Cancer Inst. 2020 06 01; 112(6):582-589.
View in:
PubMed
Modeling the natural history of ductal carcinoma in situ based on population data. Breast Cancer Res. 2020 05 27; 22(1):53.
View in:
PubMed
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575.
View in:
PubMed
Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst. 2019 09 01; 111(9):952-960.
View in:
PubMed
An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer. 2019 09 01; 125(17):3013-3024.
View in:
PubMed
Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients. Melanoma Res. 2019 02; 29(1):70-76.
View in:
PubMed
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma. Clin Cancer Res. 2019 04 15; 25(8):2494-2502.
View in:
PubMed
Clinicopathologic, misdiagnosis, and survival differences between clinically amelanotic melanomas and pigmented melanomas. J Am Acad Dermatol. 2019 May; 80(5):1292-1298.
View in:
PubMed
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res. 2019 01 15; 25(2):524-532.
View in:
PubMed
The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update. Med Decis Making. 2018 04; 38(1_suppl):44S-53S.
View in:
PubMed
Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Med Decis Making. 2018 04; 38(1_suppl):140S-150S.
View in:
PubMed
Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. Med Decis Making. 2018 04; 38(1_suppl):3S-8S.
View in:
PubMed
Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology. Med Decis Making. 2018 04; 38(1_suppl):112S-125S.
View in:
PubMed
Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches. Med Decis Making. 2018 04; 38(1_suppl):126S-139S.
View in:
PubMed
Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA. 2018 01 09; 319(2):154-164.
View in:
PubMed
Distinguishing between CISNET model results versus CISNET models. Cancer. 2018 03 01; 124(5):1083-1084.
View in:
PubMed
Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence. Cancer Prev Res (Phila). 2017 Nov; 10(11):635-640.
View in:
PubMed
Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
View in:
PubMed
Gene methylation biomarkers in sputum as a classifier for lung cancer risk. Oncotarget. 2017 Sep 08; 8(38):63978-63985.
View in:
PubMed
Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age. MDM Policy Pract. 2017 Jul; 2.
View in:
PubMed
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-a-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10; 35(8):885-892.
View in:
PubMed
Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (US Surveillance, Epidemiology, and End Results, 2005-2011). J Invest Dermatol. 2016 09; 136(9):1894-1897.
View in:
PubMed
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med. 2016 Feb 16; 164(4):215-25.
View in:
PubMed
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82.
View in:
PubMed
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics. 2015; 7:58.
View in:
PubMed
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014 Nov; 106(11).
View in:
PubMed
Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine. 2014 Nov 12; 32(48):6527-36.
View in:
PubMed
Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014 Jun; 106(6):dju092.
View in:
PubMed
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
View in:
PubMed
Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res. 2014 Apr; 24(2):150-7.
View in:
PubMed
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol. 2014 Mar; 15(3):297-304.
View in:
PubMed
HIV-1 envelope replication and a4ß7 utilization among newly infected subjects and their corresponding heterosexual partners. Retrovirology. 2013 Dec 26; 10:162.
View in:
PubMed
ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res. 2013 Dec 01; 19(23):6597-604.
View in:
PubMed
Live attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques. PLoS One. 2013; 8(9):e75556.
View in:
PubMed
Pediatric melanoma: analysis of an international registry. Cancer. 2013 Nov 15; 119(22):4012-9.
View in:
PubMed
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol. 2013 Nov 20; 31(33):4179-87.
View in:
PubMed
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One. 2013; 8(8):e69748.
View in:
PubMed
Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. J Clin Oncol. 2013 Jun 20; 31(18_suppl):CRA9007.
View in:
PubMed
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20; 31(3):373-9.
View in:
PubMed
Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer. 2012 Dec 15; 118(24):6022-30.
View in:
PubMed
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med. 2012 May 01; 156(9):609-17.
View in:
PubMed
Modeling the impact of population screening on breast cancer mortality in the United States. Breast. 2011 Oct; 20 Suppl 3:S75-81.
View in:
PubMed
Schistosoma mansoni enhances host susceptibility to mucosal but not intravenous challenge by R5 Clade C SHIV. PLoS Negl Trop Dis. 2011 Aug; 5(8):e1270.
View in:
PubMed
Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One. 2011; 6(7):e22010.
View in:
PubMed
Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine. 2011 Aug 05; 29(34):5611-22.
View in:
PubMed
Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis. 2010 Apr 15; 201(8):1155-63.
View in:
PubMed
Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010 Apr; 133(4):646-53.
View in:
PubMed
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009 Nov 17; 151(10):738-47.
View in:
PubMed
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol. 2010 Jan; 148(2):217-25.
View in:
PubMed
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res. 2009 Feb 01; 15(3):1076-85.
View in:
PubMed
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe. 2009 Jan 22; 5(1):84-94.
View in:
PubMed
Acute Schistosoma mansoni infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus exposure. PLoS Negl Trop Dis. 2008 Jul 23; 2(7):e265.
View in:
PubMed
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 01; 26(4):527-34.
View in:
PubMed
Comparison of plasma viremia and antibody responses in macaques inoculated with envelope variants of single-cycle simian immunodeficiency virus differing in infectivity and cellular tropism. J Virol. 2008 Jan; 82(1):321-34.
View in:
PubMed
Mortality modeling of early detection programs. Biometrics. 2008 Jun; 64(2):386-95.
View in:
PubMed
Coinfection with Schistosoma mansoni reactivates viremia in rhesus macaques with chronic simian-human immunodeficiency virus clade C infection. Infect Immun. 2007 Apr; 75(4):1751-6.
View in:
PubMed
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006 Jan 05; 439(7072):89-94.
View in:
PubMed
Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). Leuk Lymphoma. 2005 Jan; 46(1):55-61.
View in:
PubMed
Early detection of disease and scheduling of screening examinations. Stat Methods Med Res. 2004 Dec; 13(6):443-56.
View in:
PubMed
Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group. Leuk Res. 2004 Aug; 28(8):813-9.
View in:
PubMed
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004 Mar 15; 22(6):1078-86.
View in:
PubMed
Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS. 2004 Mar 05; 18(4):605-13.
View in:
PubMed
Modelling the early detection of breast cancer. Ann Oncol. 2003 Aug; 14(8):1199-202.
View in:
PubMed
Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood. 2003 Jan 01; 101(1):226-35.
View in:
PubMed
Statistical models for screening: planning public health programs. Cancer Treat Res. 2002; 113:19-36.
View in:
PubMed
Models and the early detection of disease: methodological considerations. Cancer Treat Res. 2002; 113:1-18.
View in:
PubMed